image
Healthcare - Medical - Care Facilities - NYSE - DE
$ 24.805
2.46 %
$ 14.6 B
Market Cap
25.84
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one FMS stock under the worst case scenario is HIDDEN Compared to the current market price of 24.8 USD, Fresenius Medical Care AG & Co. KGaA is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one FMS stock under the base case scenario is HIDDEN Compared to the current market price of 24.8 USD, Fresenius Medical Care AG & Co. KGaA is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one FMS stock under the best case scenario is HIDDEN Compared to the current market price of 24.8 USD, Fresenius Medical Care AG & Co. KGaA is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
19.5 B REVENUE
0.29%
1.37 B OPERATING INCOME
630.04%
732 M NET INCOME
-18.16%
2.63 B OPERATING CASH FLOW
21.31%
-544 M INVESTING CASH FLOW
25.93%
-1.86 B FINANCING CASH FLOW
-14.91%
4.76 B REVENUE
-0.13%
463 M OPERATING INCOME
8.87%
265 M NET INCOME
41.56%
984 M OPERATING CASH FLOW
122.51%
600 M INVESTING CASH FLOW
296.16%
0 FINANCING CASH FLOW
100.00%
Balance Sheet Fresenius Medical Care AG & Co. KGaA
image
Current Assets 8.7 B
Cash & Short-Term Investments 1.54 B
Receivables 3.64 B
Other Current Assets 3.52 B
Non-Current Assets 25.2 B
Long-Term Investments 1.08 B
PP&E 7.45 B
Other Non-Current Assets 16.7 B
Current Liabilities 6.11 B
Accounts Payable 839 M
Short-Term Debt 1.56 B
Other Current Liabilities 3.71 B
Non-Current Liabilities 13 B
Long-Term Debt 10.5 B
Other Non-Current Liabilities 2.5 B
EFFICIENCY
Earnings Waterfall Fresenius Medical Care AG & Co. KGaA
image
Revenue 19.5 B
Cost Of Revenue 14.5 B
Gross Profit 4.93 B
Operating Expenses 3.56 B
Operating Income 1.37 B
Other Expenses 637 M
Net Income 732 M
RATIOS
25.32% GROSS MARGIN
25.32%
7.04% OPERATING MARGIN
7.04%
2.57% NET MARGIN
2.57%
3.66% ROE
3.66%
1.47% ROA
1.47%
3.30% ROIC
3.30%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Fresenius Medical Care AG & Co. KGaA
image
Net Income 732 M
Depreciation & Amortization 1.75 B
Capital Expenditures -685 M
Stock-Based Compensation 32.5 M
Change in Working Capital 561 M
Others 291 M
Free Cash Flow 1.94 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Fresenius Medical Care AG & Co. KGaA
image
Wall Street analysts predict an average 1-year price target for FMS of $21.7 , with forecasts ranging from a low of $11.7 to a high of $27 .
FMS Lowest Price Target Wall Street Target
11.7 USD -52.83%
FMS Average Price Target Wall Street Target
21.7 USD -12.62%
FMS Highest Price Target Wall Street Target
27 USD 8.85%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.634 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Fresenius Medical Care AG & Co. KGaA
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Focus Graphite Advanced Materials Provides Update on Patent Pending Silicon-Enhanced Spheroidized Graphite Technology for Battery Anodes The Company's patent pending silicon-enhanced spheroidized graphite technology represents a breakthrough in lithium-ion battery performance. OTTAWA, ON / ACCESS Newswire / February 10, 2025 / Focus Graphite Advanced Materials Inc. (TSXV:FMS)(OTCQB:FCSMF)(FSE:FKC) ("Focus" or the "Company"), a Canadian critical minerals resource company developing innovative advanced battery materials and technology, is pleased to provide an update on the status of its patent applications for its proprietary silicon-enhanced spheroidized graphite technology for lithium-ion battery anodes. accessnewswire.com - 3 weeks ago
Fresenius Medical Care: A 'Buy' Going Into 2025 Fresenius Medical Care is a leader in global kidney care, showing significant growth and an 18.5% increase since my last article. The company is attractively valued, trading at less than 18.5x P/E, with a fair value estimate of at least $34/share. Risks include political factors in the US healthcare system and technological advancements, but the company's diversification and home-care model are strong positives. seekingalpha.com - 1 month ago
Fresenius (FMS) Upgraded to Strong Buy: Here's What You Should Know Fresenius (FMS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 1 month ago
Best Income Stocks to Buy for January 7th PRMB, FMS and RBA made it to the Zacks Rank #1 (Strong Buy) income stocks list on January 7, 2024. zacks.com - 1 month ago
Best Value Stocks to Buy for January 7th FMS, SVM and CNO made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 7, 2024. zacks.com - 1 month ago
Best Momentum Stocks to Buy for December 27th PAYO, TTDKY and FMS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 27, 2024. zacks.com - 2 months ago
Best Income Stocks to Buy for December 27th TTDKY, FMS and FHB made it to the Zacks Rank #1 (Strong Buy) income stocks list on December 27, 2024. zacks.com - 2 months ago
Best Value Stocks to Buy for December 27th AAL, FMS and TTDKY made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 27, 2024. zacks.com - 2 months ago
Fresenius Medical Care Listed in The Dow Jones Sustainability World Index and for the 15th Time in The Dow Jones Sustainability Europe Index Ranking puts Fresenius Medical Care among the best-in-class sustainability performers in the world and Europe The company recorded progress towards its sustainability targets Sustainability is one of the essential drivers for future BAD HOMBURG, Germany , Dec. 23, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has been recognized as a sustainability leader with the inclusion in the Dow Jones Sustainability World Index and with the inclusion in the Dow Jones Sustainability Europe Index for the 15th time. Dow Jones Sustainability Index (DJSI) is one of the world's leading ESG (Environmental, Social, Governance) stock indices. prnewswire.com - 2 months ago
Fresenius Medical Care returns to Dax 40 Index BAD HOMBURG, Germany , Dec. 20, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, will return to the top tier of the German Stock Index, the DAX 40, as of December 27, 2024. The index represents the performance of the 40 largest publicly traded companies listed on the Frankfurt Stock Exchange and accounts for around 80 percent of the market capitalization of listed stock corporations in Germany. prnewswire.com - 2 months ago
4 Value Stocks to Buy as Wall Street Awaits Fed's Rate Decision Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. TSN, GM, FMS and DLX boast a low P/CF ratio. zacks.com - 2 months ago
5 Low Price-to-Book Value Stocks to Buy as 2024 Draws to a Close The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, FMS, CIO, TRTX and ZIM are some such stocks. zacks.com - 2 months ago
8. Profile Summary

Fresenius Medical Care AG & Co. KGaA FMS

image
COUNTRY DE
INDUSTRY Medical - Care Facilities
MARKET CAP $ 14.6 B
Dividend Yield 0.00%
Description Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Contact Else-KrOener Strasse 1, Bad Homburg, 61352 https://www.freseniusmedicalcare.com
IPO Date Sept. 17, 1996
Employees 113079
Officers Mr. Martin Fischer Chief Financial Officer & Member of the Management Board Dr. Gail-Suzanne Brown Senior Vice President of Research & Development Mr. Craig Cordola FACHE, M.B.A., M.H.A. Chief Executive Officer of Care Delivery & Member of Management Board Dr. Dominik Heger Executive Vice President and Head of Investor Relations, Strategic Development & Communications Dr. Franklin W. Maddux F.A.C.P. Global Chief Medical Officer & Member of Management Board Dr. Katarzyna Mazur-Hofsab Ph.D. Chief Executive Officer of Care Enablement & Member of Management Board Mr. Glenn Slater Senior Vice President of Manufacturing and Supply Chain Operations Ms. Helen Giza Chair of Management Board & Chief Executive Officer Mr. Jorg Haring Global Head of Legal, Compliance & Human Resources and Labor Director Mr. Joachim Weith Senior Vice President of Corporate Communications & Governmental Affairs